Reassessment of recommended imipenem doses in febrile neutropenic patients with hematological malignancies

Antimicrobial Agents and Chemotherapy

Volumn 53, Issue 2, 2009, Pages 785-787

  Lamoth, F ^a   Buclin, T ^a   Csajka, C ^a   Pascual, A ^a   Calandra, T ^a   Marchetti, O ^a  

^a LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

IMIPENEM;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEBRILE NEUTROPENIA; FEMALE; GLOMERULUS FILTRATION RATE; HEMATOLOGIC MALIGNANCY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE;

ADOLESCENT; ADULT; AGED; ANTI-BACTERIAL AGENTS; ANTINEOPLASTIC AGENTS; FEMALE; GLOMERULAR FILTRATION RATE; GUIDELINES AS TOPIC; HEMATOLOGIC NEOPLASMS; HUMANS; IMIPENEM; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NEUTROPENIA; YOUNG ADULT;

EID: 59749099847     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00891-08     Document Type: Article

References (19)

1. Alou, L., L. Aguilar, D. Sevillano, M. J. Gimenez, O. Echeverria, M. L. Gomez-Lus, and J. Prieto. 2005. Is there a pharmacodynamic need for the use of continuous versus intermittent infusion with ceftazidime against Pseudomonas aeruginosa? An in vitro pharmacodynamic model. J. Antimicrob. Chemother. 55:209-213.
2. Ariano, R. E., A. Nyhlen, J. P. Donnelly, D. S. Sitar, G. K. Harding, and S. A. Zelenitsky. 2005. Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann. Pharmacother. 39:32-38.
3. Drusano, G. L. 2003. Prevention of resistance: a goal for dose selection for antimicrobial agents. Clin. Infect. Dis. 36:S42-S50.
4. Drusano, G. L., K. I. Plaisance, A. Forrest, C. Bustamante, A. Devlin, H. C. Standiford, and J. C. Wade. 1987. Steady-state pharmacokinetics of imipenem in febrile neutropenic cancer patients. Antimicrob. Agents Chemother. 31:1420-1422.
5. European Committee on Antimicrobial Susceptibility Testing (EUCAST). 2008. Antimicrobial wild type distributions of microorganisms. http://www.srga.org/eucastwt/WT-EUCAST.htm. Accessed 4 September 2008.
6. Giannoni, E., P. Moreillon, J. Cotting, A. Moessinger, J. Bille, L. Decosterd, G. Zanetti, P. Majcherczyk, and D. Bugnon. 2006. Prospective determination of plasma imipenem concentrations in critically ill children. Antimicrob. Agents Chemother. 50:2563-2568.
7. Janmohamed, R. M., M. J. Leyland, J. Kelly, and I. Farrell. 1990. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies. J. Antimicrob. Chemother. 25:407-412.
8. Mouton, J. W., D. J. Touzw, A. M. Horrevorts, and A. A. Vinks. 2000. Comparative pharmacokinetics of the carbapenems: clinical implications. Clin. Pharmacokinet. 39:185-201.
9. Mouton, J. W., and A. A. Vinks. 2005. Pharmacokinetic/ pharmacodynamic modelling of antibacterials in vitro and in vivo using bacterial growth and kill kinetics: the minimum inhibitory concentration versus stationary concentration. Clin. Pharmacokinet. 44:201-210.
10. Mouton, J. W., and A. A. Vinks. 2007. Continuous infusion of beta-lactams. Curr. Opin. Crit. Care 13:598-606.
11. Pea, F., P. Viale, A. Candoni, F. Pavan, L. Pagani, D. Damiani, M. Casini, and M. Furlanut. 2004. Teicoplanin in patients with acute leukaemia and febrile neutropenia: a special population benefiting from higher dosages. Clin. Pharmacokinet. 43:405-415.
12. Pea, F., P. Viale, D. Damiani, F. Pavan, F. Cristini, R. Fanin, and M. Furlanut. 2005. Ceftazidime in acute myeloid leukemia patients with febrile neutropenia: helpfulness of continuous intravenous infusion in maximizing pharmacodynamic exposure. Antimicrob. Agents Chemother. 49:3550-3553.
13. Sakka, S. G., A. K. Glauner, J. B. Bulitta, M. Kinzig-Schippers, W. Pfister, G. L. Drusano, and F. Sorgel. 2007. Population pharmacokinetics and pharmacodynamics of continuous versus short-term infusion of imipenem-cilastatin in critically ill patients in a randomized, controlled trial. Antimicrob. Agents Chemother. 51:3304-3310.
14. Tam, V. H., P. S. McKinnon, R. L. Akins, M. J. Rybak, and G. L. Drusano. 2002. Pharmacodynamics of cefepime in patients with gram-negative infections. J. Antimicrob. Chemother. 50:425-428.
15. Tegeder, I., A. Schmidtko, L. Brautigam, A. Kirschbaum, G. Geisslinger, and J. Lotsch. 2002. Tissue distribution of imipenem in critically ill patients. Clin. Pharmacol. Ther. 71:325-333.
16. Turnidge, J. D. 1998. The pharmacodynamics of beta-lactams. Clin. Infect. Dis. 27:10-22.
17. Viscoli, C., A. Cometta, W. V. Kern, R. Bock, M. Paesmans, F. Crokaert, M. P. Glauser, and T. Calandra. 2006. Piperacillin-tazobactam monotherapy in high-risk febrile and neutropenic cancer patients. Clin. Microbiol. Infect. 12:212-216.
18. Zajac, B. A., M. A. Fisher, G. A. Gibson, and R. R. MacGregor. 1985. Safety and efficacy of high-dose treatment with imipenem-cilastatin in seriously ill patients. Antimicrob. Agents Chemother. 27:745-748.
19. Zeitany, R. G., N. S. El Saghir, C. R. Santhosh-Kumar, and M. A. Sigmon. 1990. Increased aminoglycoside dosage requirements in hematologic malignancy. Antimicrob. Agents Chemother. 34:702-708.